News coverage about Tonix Pharmaceuticals (NASDAQ:TNXP) has been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8908515227664 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Tonix Pharma (TNXP) Announces Jessica Morris as COO – StreetInsider.com (streetinsider.com)
- Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating … – GlobeNewswire (press release) (globenewswire.com)
- Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer (finance.yahoo.com)
- TNXP: Ready to File IND to Study TNX 102-SL in Agitation in Alzheimer’s Disease (finance.yahoo.com)
Shares of Tonix Pharmaceuticals (TNXP) traded down $0.01 during trading on Friday, reaching $3.80. 30,397 shares of the company’s stock were exchanged, compared to its average volume of 60,810. Tonix Pharmaceuticals has a twelve month low of $2.85 and a twelve month high of $9.40. The firm has a market cap of $29.64, a price-to-earnings ratio of -0.80 and a beta of 2.92.
In other news, Director Ernest Mario sold 36,967 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $3.51, for a total value of $129,754.17. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $35,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 48,934 shares of company stock worth $172,496 over the last ninety days. Insiders own 4.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-tonix-pharmaceuticals-tnxp-stock-price.html.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
What are top analysts saying about Tonix Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tonix Pharmaceuticals and related companies.